LYRA - Lyra Therapeutics Inc
IEX Last Trade
0.3189
0.004 1.098%
Share volume: 686,379
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$0.32
0.00
1.11%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-11-02 | 2022-11-08 | 2023-03-29 | 2023-05-12 | 2023-08-08 | 2023-11-07 | 2024-03-22 | 2024-04-30 | |
| Assets | |||||||||
| Total Assets | 130.035 M | 119.463 M | 109.968 M | 93.868 M | 125.675 M | 120.575 M | 142.600 M | 141.527 M | |
| Current Assets | 122.381 M | 112.230 M | 100.829 M | 84.799 M | 118.253 M | 104.920 M | 104.821 M | 89.443 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.383 M | 2.343 M | 2.935 M | 2.092 M | 1.800 M | 2.370 M | 2.068 M | 2.325 M | |
| Short Term Investments | 1.383 M | 2.343 M | 2.935 M | 2.092 M | 1.800 M | 2.370 M | 2.068 M | 2.325 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 120.669 M | 109.558 M | 97.894 M | 82.707 M | 116.150 M | 102.550 M | 102.753 M | 87.118 M | |
| Total Non-current Assets | 7.654 M | 7.233 M | 9.139 M | 9.069 M | 7.422 M | 15.655 M | 37.779 M | 52.084 M | |
| Property Plant Equipment | 4.009 M | 3.753 M | 2.243 M | 2.004 M | 560.000 K | 726.000 K | 2.043 M | 3.783 M | |
| Other Assets | 2.556 M | 2.391 M | 5.504 M | 5.673 M | 5.773 M | 13.537 M | 34.344 M | 46.309 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 130.035 M | 119.463 M | 109.968 M | 93.868 M | 125.675 M | 120.575 M | 142.600 M | 141.527 M | |
| Total liabilities | 23.786 M | 26.241 M | 29.214 M | 27.777 M | 27.098 M | 36.336 M | 53.180 M | 64.023 M | |
| Total current liabilities | 10.607 M | 13.605 M | 14.470 M | 14.154 M | 14.111 M | 19.235 M | 19.597 M | 18.724 M | |
| Accounts Payable | 1.670 M | 2.900 M | 2.616 M | 3.951 M | 4.188 M | 5.054 M | 3.131 M | 2.844 M | |
| Other liabilities | 13.176 M | 12.633 M | 14.077 M | 13.432 M | 12.987 M | 12.214 M | 12.136 M | 11.943 M | |
| Current long term debt | 926.000 K | 654.000 K | 1.549 M | 1.900 M | 1.688 M | 1.403 M | 5.434 M | 4.504 M | |
| Long term debt | 3.000 K | 3.000 K | 667.000 K | 191.000 K | 0.000 | 4.887 M | 21.447 M | 33.356 M | |
| Other liabilities | 13.176 M | 12.633 M | 14.077 M | 13.432 M | 12.987 M | 12.214 M | 12.136 M | 11.943 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 106.249 M | 93.222 M | 80.754 M | 66.091 M | 98.577 M | 84.239 M | 89.420 M | 77.504 M | |
| Common stock | 33.946 M | 36.826 M | 37.161 M | 36.833 M | 43.676 M | 56.954 M | 61.754 M | 64.011 M | |
| Retained earnings | -219.674 M | -234.440 M | -248.675 M | -264.930 M | -280.548 M | -296.199 M | -311.355 M | -333.807 M |